Business
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration
INM-089 improves retinal function in in vivo preclinical AMD disease model Establishes cannabinol (CBN) analog candidate in a new disease target Vancouver,
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"\nINM-089 improves retinal function in in vivo preclinical AMD disease model\nEstablishes cannabinol (CBN) analog candidate in a new disease target\n\nVancouver, British Columbia--(Newsfile Corp. - November 29, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\"InMed\" or the \"Company\"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announces the launch of INM-089, a cannabinol (\"CBN\") analog, to investigate its effects in the treatment of Age-related Macular Degeneration (\"AMD\"). INM-089 is the company's second ocular pharmaceutical program.\nResults from a study, conducted under a collaborative research agreement with leading cannabinoid expert Dr. Mauro Maccarrone at the Università degli Studi dell'Aquila (Italy), demonstrated that INM-089 preserved retinal function in an in vivo AMD disease model. Furthermore, in this model, treatment with INM-089 also improved the thickness of the outer nuclear layer (\"ONL\") of the retina where the photoreceptors are located. Based on widely accepted ocular research, there is a very strong correlation between the thickness of the ONL, photoreceptor preservation and visual acuity.\nSeveral CBN analog structures were screened in in vitro and in vivo models to select the most appropriate candidate for continued development. InMed selected a specific CBN analog that outperformed its natural cannabinoid counterpart and demonstrated promising effects related to the treatment of AMD.\n\"We are very pleased that this research has led to the identification of a lead CBN analog candidate to advance to additional in vivo studies as part of the preclinical development program. Early studies show promising neuroprotective effects of INM-089, leading to the preservation of the retinal function at the back of the eye. Neuroprotection in AMD remains an unmet medical need and a new treatment option may help solve this multifactorial disease,\" said InMed's scientific advisor, Dr. Mauro Maccarrone.\n\"The INM-089 program, in conjunction with the work we are doing in glaucoma (INM-088), expands our ocular pipeline to treat both front of eye and back of eye indications, including AMD,\" said Dr. Eric Hsu, SVP of Preclinical R&D at InMed.\nFrom previous ocular research of the parent, naturally occurring cann...